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Abstract
Background: In pregnancy lipid levels increase with gestation resembling an atherogenic lipid profile. Currently it is
unclear whether gestational lipid levels are associated with an adverse cardiovascular risk profile later in life. The
aim of this study is to assess the association between gestational lipid levels and lipid levels and prevalence of the
metabolic syndrome (MS) six years after pregnancy.
Methods: In plasma of 3510 women from the Generation R Study; a prospective population-based cohort, we
measured lipid levels (total cholesterol, triglycerides and high-density lipoprotein cholesterol [HDL-c]), and low-
density lipoprotein cholesterol (LDL-c), remnant cholesterol and non-HDL-c were calculated in early pregnancy
(median 13.2 weeks, 90% range [10.5 to 17.1]) and six years after pregnancy (median 6.5 years, 90% range [6.2
to 7.8]). MS was assessed six years after pregnancy according to the NCEP/ATP3 criteria. We also examined
the influence of pregnancy complications on these associations.
Results: Gestational lipid levels were positively associated with corresponding lipid levels six years after
pregnancy, independent of pregnancy complications. Six years after pregnancy the prevalence of MS was
10.0%; the prevalence was higher for women with a previous placental syndrome (13.5%). Gestational
triglycerides and remnant cholesterol in the highest quartile and HDL-c in the lowest quartile were associated
with the highest risk for future MS, independent of smoking and body mass index.
Conclusions: Gestational lipid levels provide an insight in the future cardiovascular risk profile of women in
later life. Monitoring and lifestyle intervention could be indicated in women with an unfavorable gestational
lipid profile to optimize timely cardiovascular risk prevention.
Keywords: Pregnancy, Metabolic syndrome, Lipoproteins, HDL, Triglycerides, Cholesterol, LDL, Placental
syndrome
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Background
Pregnancy has been proposed as a natural ‘stress test’ to pre-
dict the risk of cardiovascular disease (CVD) later in life [1].
The long-term effect of high blood pressure during preg-
nancy has been well established [2–6]. Women who develop
a hypertensive disorder of pregnancy such as gestational
hypertension or pre-eclampsia have a 2–8 times higher risk
of developing chronic hypertension, metabolic syndrome and
CVD later in life compared to women with an uncompli-
cated pregnancy [3, 7–11]. Less is known about the long
term cardiovascular effect of gestational lipid levels.
In pregnancy lipid levels rise, leading to 30% higher
levels of cholesterol, triglycerides and LDL-c at the end of
the 3rd term [12–15]. The gestational lipid profile there-
fore shows resemblance to an atherogenic lipid profile.
After delivery, lipid levels in general normalize to pre-
pregnancy levels within three to four months [16–18].
Previously it has been shown that women with an ad-
verse gestational lipid profile have an increased risk of
gestational hypertension and pre-eclampsia [19, 20]. The
other way around, women with a hypertensive disorder
of pregnancy also show a more atherogenic lipid profile
six years after pregnancy than women with a previous
normotensive pregnancy which may contribute to their
increased CVD risk in later life [21].
Currently, it is unknown whether the gestational lipid
profile, similar to gestational blood pressure, may provide
a glimpse of the future cardiovascular health. Moreover it
is unknown if body mass index (BMI) is the main driver
for the association between gestational lipid levels and
lipid levels years after pregnancy. Therefore, the aim of
this study is to assess the association between gestational
lipid levels with lipid levels and prevalence of the meta-
bolic syndrome six years after pregnancy and to explore to
what extent these associate with smoking and BMI. More-
over, as women with pregnancy complications may have a
more adverse lipid profile we assessed the incidence of
metabolic syndrome and repeated all analyses in women
with and without a pregnancy complicated by the placen-
tal syndrome (pre-eclampsia, a child born small-for-
gestational age and spontaneous preterm birth).
Methods
Design and study population
This study was embedded in the Generation R study, an
ongoing population-based prospective cohort study from
early pregnancy onwards in Rotterdam, the Netherlands
[22]. Ethical approval for this study was obtained by the
Medical Ethics Committee of the Erasmus University
Medical Centre (Erasmus MC), Rotterdam, the
Netherlands (MEC-2007-413). For this study, we in-
cluded women with a live born singleton or twin. We
excluded women without available lipid measurements
during and/or six years after pregnancy, and women
taking lipid lowering medication at intake (Fig. 1). Writ-
ten informed consent was obtained from all participants.
Additional file 2 contains a Strengthening the Reporting
of Observational Studies in Epidemiology (STROBE)
statement for the current study [23].
Exposure: lipid levels in early pregnancy
Non-fasting blood samples were obtained via venous
puncture in early pregnancy (median 13.2 weeks, 90%
range [10.5 to 17.1]).
Outcome: lipid levels six years after pregnancy
Non-fasting blood samples were obtained via venous
puncture six years after pregnancy (median 6.5 years,
90% range [6.2 to 7.8]). All samples were taken by
trained research nurses and stored at the research facility
at room temperature for a maximum of three hours,
after which they were sent to a dedicated laboratory fa-
cility [22, 24]. Glucose levels, total cholesterol, triglycer-
ides and HDL-c concentrations were measured with the
Vital Scientific (Merck) Selectra E Chemistry Analyzer.
LDL-c, remnant cholesterol and non-HDL-c were calcu-
lated [25]. Details of processing procedures and lipid cal-
culations have been described previously [20, 21, 24].
Outcome: metabolic syndrome
Systolic blood pressure and diastolic blood pressure were
measured six years after pregnancy using a validated
Omron 907 automated digital oscillometric sphygmo-
manometer (OMRON Healthcare Europe BV, Hoofd-
dorp, the Netherlands) [26]. According to the NCEP,
ATP III criteria, metabolic syndrome was defined as hav-
ing three or more of the following parameters: waist cir-
cumference (> 88 cm); triglyceride levels (≥ 150 mg/dL /
≥ 1.70 mmol/L) or drug treatment for elevated triglycer-
ides; HDL-c (< 50 mg/dL / < 1.30 mmol/L for women);
blood pressure (≥ 130 / ≥ 85mmHg) or drug treatment
for hypertension, and fasting glucose (≥ 110 mg/dL) or
the use of glucose lowering medication [27]. Non-fasting
glucose measured six years after pregnancy ≥ 7.8 mmol/
L was used as a proxy for fasting glucose according to
the cut-offs of the International Diabetes Federation.
Waist circumference was measured ten years after preg-
nancy (median 9.7 years, 90% range [9.5 to 10.3]) at the
minimum circumference between the iliac crest and the
rib cage and was used as a proxy for waist circumference
six years after pregnancy.
Placental syndrome
Placental syndrome was defined as having pre-eclampsia,
a child born small-for-gestational age (SGA) or a spon-
taneous preterm birth (sPTB) in the index pregnancy.
We obtained information on clinically diagnosed pre-
eclampsia from medical records that were cross-checked
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with the original hospital charts [28]. Pre-eclampsia was
defined, using the ISSHP criteria that were in effect at
the time of the study, as the development of SBP ≥ 140
mmHg and/or a DBP ≥ 90mmHg with new-onset pro-
teinuria in a random urine sample and no evidence of a
urinary tract infection [29]. Midwife and hospital regis-
tries provided information on gestational age at birth,
birth weight and child’s sex. SGA was defined as a child
with a birth weight below the 10th percentile adjusted
for gestational age and sex of the child. We defined
sPTB as the spontaneous onset of labour before 37
weeks of gestation.
Lifestyle factors and anthropometrics
Information on characteristics during pregnancy includ-
ing maternal age, ethnicity, educational level, parity,
smoking and information on folic acid supplementation
was obtained by questionnaires. Six years after preg-
nancy, questionnaires were used to obtain information
on cholesterol and glucose lowering medication. Height
(cm) and weight (kg) were obtained in early pregnancy
(median 13.2 weeks of gestational age, 90% range [10.5
to 17.1] weeks). Height was measured at the research
facility without shoes and weight was measured without
heavy clothing. Body mass Index (BMI) (kg/m2) was cal-
culated based on measured weight and height. Pre-
pregnancy BMI was obtained from questionnaires. The
pre-pregnancy weight and the weight measured at enrol-
ment in early pregnancy were highly correlated (Pear-
son’s correlation coefficient 0.96 [P-value < .001]).
Therefore, pre-pregnancy weight was used in the
analyses.
Statistical analyses
We examined pregnancy and follow-up characteristics
for all women (Table 1). We examined the distribution
of lipid levels in early pregnancy for all women with and
without the metabolic syndrome six years after preg-
nancy (Table 2). The presented P-values are the result of
Student t test for variables with a normal distribution
and Mann-Whitney U test for variables with a skewed
distribution. Triglyceride and remnant cholesterol levels
were log transformed to achieve a normal distribution.
To enable comparison of effect estimates, we con-
structed SD-scores (SDS) of all lipid levels. We exam-
ined the incidence of metabolic syndrome and stratified
Fig. 1 Flowchart
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this by its components (Fig. 3). We imputed missing
values in confounders that were used for linear and lo-
gistic regression analyses. We used the Markov Chain
Monte Carlo multiple imputation procedures to reduce
potential bias attributable to missing data [30]. Data
were analyzed in each set separately, and pooled esti-
mates from the five imputed data sets were used to re-
port the effect estimates and their 95% confidence
interval. For the multiple imputation procedure we per-
formed ten iterations [31]. In this study 5.0% of women
had missing information on educational level, 1.3% on
ethnicity, 0.5% on parity, 9.3% on smoking, 21.3% on
folic acid supplementation and 16.5% on pre-pregnancy
BMI. To relate lipid levels in early pregnancy to lipid
levels and metabolic syndrome six years after pregnancy
we performed linear and logistic regression analyses
(Table 3 and Additional file 1: Table S1). To assess whether
the association of lipid levels in early pregnancy and meta-
bolic syndrome was stronger in women with higher concen-
trations of lipid levels (total cholesterol, triglycerides, LDL-c,
remnant cholesterol and non-HDL-c) in early pregnancy and
respectively lower levels of HDL-c, lipid levels in early preg-
nancy were categorized as quartiles and subsequently used as
a categorical measure (Fig. 2). Confounders that were in-
cluded in the regression models were selected based on their
associations with the exposure and outcomes of interest and
based on previous studies. The selected confounders in-
cluded: maternal age at intake, gestational age at blood sam-
pling, educational level, ethnicity, parity, smoking, and folic
acid supplementation. For the association of gestational lipid
levels with lipid levels six years after pregnancy, pre-
pregnancy BMI was additionally added to the regression
models. In attempt to exclude the effect of placental
syndromes, we examined the incidence of metabolic
syndrome in this subgroup of women and repeated all
the analyses excluding women with a placental syn-
drome in their index pregnancy (Fig. 3). A nonre-
sponse analysis was conducted by comparing the
characteristics of women included in this study (n =
3510) to women without available lipid levels six
years after pregnancy (n = 2340) (Additional file 1:
Table S2). Statistical analyses were performed using
the IBM Statistical Package of Social Sciences version
24.0 for Windows (SPSS Inc., Chicago, IL).
Results
This study included a total of 3510 women (Table 1).
Women were on average 30.3 years old and 13.2 weeks
pregnant when they entered the study. 64.3% had a
European ethnicity, 47.1% was highly educated, 63.4%
was nulliparous at intake and they had on average a pre-
pregnancy BMI of 22.7 kg/m2.
Table 1 Characteristics of the total population (n = 3510)
Outcomes in pregnancy Mean (SD) or
Median (90% range)
Age mother, years 30.3 (4.8)
Gestational age at blood sampling, weeks 13.2 (10.5 to 17.1)
Non-European ethnicity, n (%) 1254 (35.7)
Low educational level, n (%) 317 (9.0)
Nulliparous, n (%) 2226 (63.4)
Pre-pregnancy BMI, kg/m2 22.7 (18.8 to 32.0)
Smoking during pregnancy, n (%) 947 (27.0)
No folic acid supplementation, n (%) 836 (23.8)
SBP in early pregnancy, mmHg 116.0 (12.4)
DBP in early pregnancy, mmHg 68.5 (9.6)
Total cholesterol, mmol/L 4.84 (0.88)
Triglycerides, mmol/L 1.26 (0.72 to 2.33)
LDL-c, mmol/L 2.43 (0.73)
HDL-c, mmol/L 1.79 (0.35)
Remnant cholesterol, mmol/L 0.57 (0.33 to 1.06)
Non-HDL-c, mmol/L 3.05 (0.84)
Glucose, mmol/L 4.38 (0.85)
Gestational age at birth, weeks 40.1 (36.9 to 42.1)
Birth weight, g 3414 (558)
Small-for-gestational age, n (%) 350 (10.0)
Spontaneous preterm birth, n (%) 125 (3.6)
Pre-eclampsia, n (%) 80 (2.4)
Six years after pregnancy
Interval time, years 6.5 (6.2 to 7.8)
Age mother, years 37.0 (4.8)
Maternal BMI, kg/m2 24.4 (19.7 to 35.0)
Total cholesterol, mmol/L 4.87 (0.89)
Triglycerides, mmol/L 1.14 (0.61 to 2.51)
LDL-c, mmol/L 2.91 (0.78)
HDL-c, mmol/L 1.37 (0.33)
Remnant cholesterol, mmol/L 0.52 (0.28 to 1.13)
Non-HDL-c, mmol/L 3.50 (0.89)
Glucose, mmol/L 5.47 (0.99)
Waist circumference, cm 82.8 (11.0)
SBP, mmHg 119.2 (12.7)
DBP, mmHg 70.6 (9.9)
Metabolic syndrome, n (%) 350 (10.0)
Data are presented as mean (SD), median (90% range) or number of subjects
(valid percentage) depending on normal or skewed distributions. Covariates
are imputed. Waist circumference was measured ten years after pregnancy.
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-
c, Low-density lipoprotein cholesterol; HDL-c, High-density
lipoprotein cholesterol; BMI, body mass index
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Early gestational lipid levels and lipid levels six years
postpartum
Total cholesterol, triglycerides, LDL-c, HDL-c, remnant
cholesterol and non-HDL-c levels were positively associ-
ated with their corresponding lipid level six years after
pregnancy (Additional file 1: Table S1). These associa-
tions were independent of pre-pregnancy BMI.
Early gestational lipid levels and metabolic syndrome six
years postpartum
Six years after pregnancy, 350 (10.0%) women were clas-
sified as having metabolic syndrome. 47.1% of women
with (gestational) diabetes mellitus or women with glu-
cose lowering medication in pregnancy developed meta-
bolic syndrome six years later. The prevalence of
metabolic syndrome in women with diabetes mellitus
and/or glucose or cholesterol lowering medication at
follow-up was 68.2%. Compared to women without
metabolic syndrome, women with metabolic syndrome
six years after pregnancy had a more atherogenic plasma
lipid profile in early pregnancy, significant for all ana-
lyzed lipids (P-value < .001) (Table 2).
Table 3 shows the association between maternal lipid
levels in early pregnancy with metabolic syndrome six
years after pregnancy. Women with higher levels of total
cholesterol, triglycerides, LDL-c, remnant cholesterol
and non-HDL-c levels in early pregnancy were more at
risk of developing metabolic syndrome six years after
pregnancy. These associations remained statistically sig-
nificant after adjustment for confounders. HDL-c was
negatively and independently associated with metabolic
syndrome.
Figure 2 shows that compared to total cholesterol
and LDL-c levels in the lower quartile, those in the
highest quartile were associated with an increased risk
of metabolic syndrome (OR 2.13, 95% CI [1.52 to
2.99] and OR 2.20, 95% CI [1.58 to 3.06], respect-
ively). Compared to HDL-c levels in the highest quar-
tile, those in the lower quartiles were associated with
an increased risk of metabolic syndrome, with the
highest risk for women in the lowest quartile (OR
7.91, 95% CI [5.09 to 12.29]). Compared to triglycer-
ides and remnant cholesterol levels in the lowest
quartile, early pregnancy levels in the second, third
and fourth quartile were associated with an increased
risk of metabolic syndrome (P-value for trend analysis
< .001). Women with triglyceride and remnant choles-
terol levels in the highest quartile had the highest risk
of metabolic syndrome (OR 13.61, 95% CI [8.02 to
23.10] and OR 13.46, 95% CI [7.93 to 22.85], respect-
ively). Compared to non-HDL-c levels in the lowest
quartile, early pregnancy non-HDL-c levels in the






Total cholesterol, mmol/L 4.81 (0.87) 5.09 (0.90) < 0.001
Triglycerides, mmol/L 1.22 (0.71 to 2.19) 1.66 (1.00 to 3.09) < 0.001
LDL-c, mmol/L 2.41 (0.72) 2.68 (0.78) < 0.001
HDL-c, mmol/L 1.81 (0.34) 1.58 (0.33) < 0.001
Remnant cholesterol, mmol/L 0.55 (0.32 to 1.00) 0.75 (0.45 to 1.37) < 0.001
Non-HDL-c, mmol/L 3.00 (0.82) 3.50 (0.88) < 0.001
Data are presented as mean (SD) or as median (90% range) depending on normal or skewed distributions. Differences between groups are tested through a
Students t test or Mann Whitney U test. Abbreviations: LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol







Total cholesterol, SDS Reference 1.30 (1.16 to 1.45) < 0.001
Triglycerides, SDS Reference 2.43 (2.14 to 2.75) < 0.001
LDL-c, SDS Reference 1.36 (1.22 to 1.51) < 0.001
HDL-c, SDS Reference 0.51 (0.46 to 0.58) < 0.001
Remnant cholesterol, SDS Reference 2.43 (2.14 to 2.76) < 0.001
Non-HDL-c, SDS Reference 1.66 (1.49 to 1.86) < 0.001
Values are odds ratios (95% confidence interval) derived from multiple logistic regression analyses. Basic model: adjusted for maternal age, gestational age at
blood sampling, ethnicity, educational level, parity, smoking and folic acid supplementation. Abbreviations: SDS, SD-scores; CI, confidence interval; OR, odds ratio;
LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol
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Fig. 2 Association of maternal lipid levels in early pregnancy in quartiles with metabolic syndrome six years after pregnancy (n = 3510). Values are
odds ratios (95% confidence interval) derived from multiple logistic regression analyses. Presented data are adjusted for maternal age, gestational
age at blood sampling, ethnicity, educational level, parity, smoking, and folic acid supplementation. Abbreviations: OR, odds ratio; CI, confidence
































Fig. 3 Characteristics of participants with and without metabolic syndrome. Metabolic syndrome according to the ATP III Diagnostic criteria.
Metabolic syndrome is stratified by its components. For each component, the valid percentages of participants with and without metabolic
syndrome are presented. Abbreviations: HDL-c, high-density lipoprotein cholesterol
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third and fourth quartile were associated with an in-
creased risk of metabolic syndrome, with the highest
risk for women in the highest quartile (OR 4.05, 95%
CI [2.79 to 5.88]).
Metabolic syndrome and its components
The most common feature of metabolic syndrome was
low HDL-c (40.0%) followed by abdominal obesity
(25.6%), high triglycerides (19.7%), a high blood pressure
(19.0%), and high glucose levels (2.3%) (Fig. 3).
Women without placental syndrome vs women with
placental syndrome
Of the 2775 women without a placental syndrome in
their index pregnancy, 239 (8.6%) were classified as hav-
ing metabolic syndrome six years after their index preg-
nancy. The prevalence of individual MS components
were comparable to those of the total population: low-
HDL-c 38.9%, abdominal obesity 24.5%, high triglycer-
ides 18.9%, high blood pressure 16.5%, and high glucose
levels 2.2% (Fig. 3).
Of the 527 women with a placental syndrome in their
index pregnancy, 71 (13.5%) were classified as having
metabolic syndrome six years after pregnancy. Their
most common feature of metabolic syndrome was also
low HDL-c (42.0%) followed by abdominal obesity
(25.4%), a high blood pressure (23.3%), high triglycerides
(22.4%), and high glucose levels (2.5%) (Fig. 3).
Women with a placental syndrome had a higher risk
(OR 1.55, 95% CI [1.15 to 2.07]) to develop metabolic
syndrome six years after pregnancy compared to women
without a placental syndrome.
In addition, the results of our regression analyses were
not influenced by placental syndrome since the results
were comparable when the analyses were repeated in a
subset of women without placental syndrome in their
index pregnancy (n = 2775) (data not shown).
Discussion
This study shows that lipid levels in early pregnancy are
positively associated with lipid levels and the prevalence
of metabolic syndrome six years after pregnancy. These
associations remained significant after correction for
smoking and BMI.
Previous studies on lipid levels measured in pregnancy
and later in life are mostly limited to measurements up
to one year postpartum [16, 17, 32]. These studies show
that lipid levels initially decrease in pregnancy followed
by a gradual increase and peak at the end of the third
trimester. Lipid levels decline to plateau at four months
after the delivery [18]. Postpartum total cholesterol
levels and LDL-c levels remain somewhat but are signifi-
cantly higher than the levels measured before pregnancy.
However, these studies do not report on the association
of gestational lipid levels with lipid levels after preg-
nancy. A previous study performed within the Gener-
ation R study population found that lipid levels in early
pregnancy increase moderately with advancing gesta-
tional age in the time-frame when lipids in this study
were measured [20]. Results from this study show that
lipid levels measured in early pregnancy may already be
indicative for lipid levels six years later, independent of
smoking and BMI. Since early pregnancy lipid levels are
also associated with adverse pregnancy outcomes and
blood pressure during and after pregnancy [20], meas-
urement of lipid levels in early pregnancy may improve
short and long-term health of women.
The prevalence of metabolic syndrome in our rela-
tively young and highly educated population of women
was 10.0%. Data on prevalence of metabolic syndrome in
young women is scarce. Notably it is much lower than
the prevalence of 22–28% of metabolic syndrome ob-
served in American women aged 30–49 years described
in the National Health and Nutrition Examination Sur-
vey (NHANES) [33]. A possible explanation may be that
their mean BMI was higher and that their educational
level was lower which is associated with an increased
risk of metabolic syndrome [34].
Previous studies assessed the prevalence of metabolic
syndrome in women who experienced hypertensive dis-
orders of pregnancy, however almost all of these studies
lacked a control group. Within these populations some
found that women with early-onset pre-eclampsia had a
higher risk of developing metabolic syndrome [8],
whereas others did not find such an association [35]. A
Canadian study, consisting of 217 women, found that
the prevalence of metabolic syndrome after one and
three years after pregnancy was 18.2% and 21.9% in
women with previous pre-eclampsia and 6.8 and 6.4% in
women without pre-eclampsia [36]. The mean BMI in
that study was higher compared to that in our study
(28.7 kg/m2 and 26.3 kg/m2 in women with and with-
out pre-eclampsia compared to 24.4 kg/m2 in our
population), which may account for the higher inci-
dence of MS.
We hypothesized that BMI would be the main risk fac-
tor driving the association between gestational lipids and
the lipid profile six years after pregnancy. However,
these associations remained significant also after adjust-
ing for pre-pregnancy BMI. Lipid levels are partially de-
termined by lifestyle factors, but also by genetics [37,
38]. A recent study found that in a healthy population of
women LDL-c levels ≥ 99th percentile were in 45.5% of
the cases explained by unfavorable genotypes or muta-
tions associated with hypercholesterolemia [37]. Several
other studies also found that genetic background has a
large influence on lipid concentrations which may be the
reason why these associations remain significant after
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adjusting for BMI [38–40]. This is interesting since it
suggests that lipid levels have a certain level of stability;
independent of lifestyle factors. Therefore, unfavorable
lipid levels may be an early marker for future cardiovas-
cular risk. In our population the majority of women
remained in the same quartile in pregnancy and six years
after pregnancy (data not shown), supporting this hy-
pothesis. As shown in previous studies, women with a
placental syndrome have an increased risk of metabolic
syndrome and CVD later in life [41]. Therefore, we per-
formed the same analyses in a subset of women without
placental syndromes. This did not affect our results. We
therefore hypothesize that our results may be explained
by genetic inheritance and to a lesser extent by lifestyle
or pregnancy-related factors. Unfortunately, the nature
of our study did not allow further investigation of this
genetic contribution.
In young, fertile women monitoring of lipid levels may
be relevant due to the association with CVD later in life.
Currently, guidelines of the American Heart Association
and guidelines of the European Society of Cardiology do
not advice to determine gestational lipid levels [42, 43].
However, in our opinion adding lipids to the routine
blood measurements in early pregnancy may provide an
opportunity to early identify women with an increased
CVD risk profile. This may be beneficial for timely inter-
vention and prevention of metabolic syndrome and sub-
sequently possible CVD in later life. Especially as
women are more prone to improve lifestyle during preg-
nancy [44].
Strengths and limitations
Strengths of our study are the prospective and struc-
tured data collection from early pregnancy onwards. We
also have a large sample of 3510 women with blood
samples six years after pregnancy available. Some limita-
tions need to be considered. First, blood samples were
obtained in a non-fasting state. However, according to
the joint consensus statement from the European Ath-
erosclerosis Society and the European Federation of
Clinical Chemistry and Laboratory Medicine lipids and
lipoproteins change minimally in response to normal
food intake [45].
Second, pre-pregnancy BMI was self-reported. Never-
theless, pre-pregnancy BMI was strongly correlated with
BMI measured in early pregnancy, which makes mis-
classification unlikely.
Third, waist circumference was only measured ten
years after pregnancy. However, weight measured six
years after pregnancy was highly correlated to weight
measured ten years after pregnancy, as did BMI six and
ten years after pregnancy (Pearson’s correlation coeffi-
cients, r 0.91 and 0.91, respectively [P < .001]). Therefore,
we assumed that waist circumference ten years after
pregnancy could be used as a proxy for waist circumfer-
ence six years after pregnancy.
Finally, similar to other studies, the non-response six
years after pregnancy may have led to selection of rela-
tively healthy women, which may affect the
generalizability of results to high-risk populations (Add-
itional file 1: Table S2).
Conclusion
The gestational lipid profile is associated with the lipid
profile and metabolic syndrome six years after preg-
nancy, independent of smoking and BMI. Having a more
atherogenic gestational lipid profile may act as an early
risk marker for CVD later in life. Therefore, monitoring
and possibly even early intervention should be indicated
in women with a more atherogenic gestational lipid pro-
file to diminish the cardiovascular burden later in life.
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